ProMIS Neurosciences is trading 10.89% lower at $8.51, with biotech-sector weakness a possible contributor.
- No company-specific announcement explaining the October 13 decline was identified; the company’s latest listed release is dated October 6.
- The provided context reports XBI down 2.01% during the session, while major market indices were only slightly lower. The sector move provides context but does not establish the cause of the sharper decline.